biotech / news / / Barchart
Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines.
Moderna's revenue surged 260% year-over-year to $389 million due to international contracts.
KEY POINTS
- Despite Q1 revenue beat, MRNA shares dropped 1.2% due to a litigation settlement charge.
- Analysts expect Moderna's loss per share to increase by 9.5% to $7.95 this fiscal year.
- Moderna is trading above its mean price target, but upside potential exists up to $135 per share.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →